It was reported that on (b)(6) 2017, the patient has a neurosurgical examination and mild redness around the surgical area was noted.The following day, laboratory testing was conducted that included cerebrospinal fluid (csf) testing that resulted in gram positive on cocci clusters stain.Another csf sample was drawn from the ommaya that was implanted on (b)(6) 2017.C-reactive proteins (crp) were noted as normal.During an infusion on the same day, the patient continued to have mild redness around the surgical area.Following the infusion, it was noted that the patient had an elevated white blood cell count (wbc) (140) so additional tests were performed that included a full blood count (cbc) and a csf testing; the cbc was normal and results of the csf testing were not provided.The elevated wbc was later updated to meningitis staphylococcal.On (b)(6) 2017, the patient experienced seizures during an infusion.An hour later, the patient developed a fever of 103°f and some irritability so a repeat csf sample was taken (b)(6) and showed an increased csf-wbc of 140.Intravenous (iv) ceftriaxone/vancomycin were administered for 14 days.The ommaya device was then tested and it was confirmed that it was negative staphylococcus aureus; however, it was decided to surgically remove the product on an unknown date.During the removal, a subgaleal collection of pus from the wound was noted.A swab was taken from the collection and it tested positive for staph.On (b)(6) 2017, the patient experienced "tight fisting" with abnormal posture of the hands.The following day, the patient experienced a fever, abnormal posturing of the feet, full body myoclonic jerks, and neck rigidity so the antibiotics were shifted to nafcillin.On (b)(6) 2017, the culture results and the csf from a lumbar puncture showed negative results.An mri of the patient's brain was then performed and showed signs of meningitis and ventriculitis, but no abscess was noted.It was then reported that in addition to the previously reported adverse events, the patient also lost their ability to swallow, which required an insertion of a nasogastric (ng) tube.Clobazam was then administered on (b)(6) 2017.On (b)(6) 2017, the patient was discharged from the hospital.The event was considered resolved with sequelae on an unknown date; the sequelae was noted as "jerks".
|
Additional information was received from a health care provider (hcp) regarding a patient whose indications for use included batten's disease.It was reported that there were no issues with the device noted on the surgical report.It was noted, however, that the patient experienced a change in mental status with seizures.It was also noted that following the explant a culture was taken and resulted in staphylococcus aureus - oxacillin susceptible; the report was finalized on (b)(6) 2017.Following the explant procedure, the patient was taken to the intensive care unit in a serious, but stable condition.When inquired about any environmental / external / patient factors that may have led or contributed to the issue, it was reported that it was unclear.The health care provider (hcp) suspected it was related to wound healing from the initial implant procedure.
|